Chelsea

Researchers are evaluating the feasibility, safety, and early effectiveness of a ketamine-assisted group therapy designed for Spanish-speaking adults experiencing depression. This pilot clinical trial focuses on adults aged 18 to 64 who meet the criteria for major depressive disorder and speak Spanish, aiming to adapt this intervention culturally within a community setting. Participants will receive ketamine-assisted psychotherapy delivered in a group format. This intervention is being studied to understand how well it works and how safe it is for Spanish-speaking adults with depression. The trial includes a one-week follow-up after the intervention to assess outcomes. During the study, participants will be monitored for safety and response to the group therapy. Researchers will evaluate the therapy's feasibility and safety one week after treatment completion. Participants must have an established psychiatrist and primary care provider to support their care throughout the trial.

This research aims to evaluate a new screening method using artificial intelligence (AI) to detect glaucoma, a chronic eye disease that can cause irreversible vision loss. The study focuses on people with diabetes as they have a higher risk of developing glaucoma. By adding glaucoma screening to existing diabetic eye disease screenings, the study hopes to catch glaucoma early and reduce the chance of blindness. Participants will have a photograph taken of the back of their eye (fundus) as part of their diabetic eye screening. Their eye pressure will also be measured using a special device called an Icare tonometer. If glaucoma is suspected, participants may undergo a side vision test using a virtual reality headset. This screening program combines AI analysis of eye images with eye pressure checks and visual field testing to improve detection. During the study, participants will have their fundus images and eye pressure measured, with visual field tests added if needed. The study will track how well this combined AI-based screening finds glaucoma cases one year after initial screening. Researchers hope this approach will provide a cost-effective way to improve glaucoma detection in community health settings and support early treatment to protect vision.